Marcus Vinicius R. Pinto, M.D., M.S.

Open

• A Phase 2, Open-label, Proof-of-Concept Study To Investigate The Efficacy, Safety, And Tolerability Of TAK-411 In Adult Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (The CASCA Study) Rochester, MN CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over time, these nerves lose their ability to send signals to the muscles in the body. This leads to muscle weakness and loss of sensation in arms and legs among other symptoms. Participants with CIDP can be treated with a protein called immunoglobulin (or IG).
  
  TAK-411 is a special type of immune globulin G (hsIgG) that has been chemically changed. It is made from IG that comes from human plasma. This study will test if TAK-411 can decrease inflammation and improve symptoms of CIDP.
  
  The main aim of this study is to check how TAK-411 affects the physical functioning of adults with CIDP when compared with results of the placebo group of a historical trial.
  
  Participants may be treated with TAK-411 for up to 1 year (51 weeks) and will be followed up for 3 weeks after last dose.
  
  During the study, participants may visit their study clinic up to approximately 21 times.
• TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study To Evaluate The Efficacy And Safety Of Nucresiran In Patients With Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN) Rochester, MN

  The purpose of this study is to:
  
  * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed
  * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels

• Validation of the Norfolk Quality of Life-diabetic neuropathy scale in Diabetic Lumbosacral Radiculoplexus Neuropathy Rochester, MN

  The purpose of this study is to bridge the existing gap by assessing the reliability and validity of the Norfolk QOL-DN questionnaire for patients with Diabetic Lumbosacral Radiculoplexus Neuropathy (DLRPN).